Demand for Fragment-based Drug Discovery Propelled by Shift towards Design-intensive Methods

The fragment-based drug delivery (FBDD) market is witnessing a rising demand in the global arena since the past few years. The paradigm shift towards design-intensive methods from traditional techniques of lead discovery such as high- throughput screening (HTS) has propelled the demand for FBDD significantly.

In addition to this, the advent of simpler, as well as less time-consuming lead discovery techniques, is expected to boost the global FBDD market remarkably in the coming years. The streamlined and easy access to highly advanced biophysical techniques is also projected to add substantially to the growth of this market in the near future.

Transparency Market Research (TMR) has recently published a market study on the global FBDD market. According to the report, the market is likely to post a healthy CAGR of 14.40% during the period from 2015 to 2023 and increase from a value of US$0.4 bn in 2014 to US$1.2 bn by the end 2023.

Asia Pacific to Register Exponential Growth in Global FBDD Market

North America acquired the leadership in the global FBDD market in 2014. The rising adoption of FBDD technique by pharmaceutical enterprises has substantially stimulated this market in North America. Asia Pacific, however, is likely to witness an exponential rise in the FBDD market in the coming years on account of the increasing research and development activities in the field of FBDD in this region.

Latest Activities by Key Players in Global FBDD Market

Sygnature Discovery, Astex Pharmaceuticals, Nuevolution, Alveus Pharmaceuticals Pvt. Ltd., Charles River Laboratories International Inc., Emerald BioStructures Inc., Kinetic Discovery Ltd., and Sprint Bioscience are the major participants in the global fragment-based drug discovery market. Here is a snapshot of the latest activities of these players that can influence this market at large.

  • Astex has recently become a partner in the Dementia Consortium. The company is looking forward to applying its expertise in fragment-based drug design to this venture.
  • Nuevolution, a Denmark-based company operating in small molecule drug discovery, has announced its partnership with Janssen Biotech Inc., a subsidiary of Johnson and Johnson. According to the partnership agreement, Nuevolution will utilize ‘Chemetics’, its drug discovery platform, to discover and develop drug candidates against the drug targets picked out by Janssen.
Though the global market for FBDD looks flourishing on the whole, the low potency level in a few compounds, derived from fragment screening, and the need for a high protein and a unique fragment library to conduct studies are likely to restrict the market from reporting a steady rise in the coming years. However, the inclusion of computational biology in biophysical techniques is expected to open doors for novel opportunities for the market.

Additionally, the untapped growth opportunities available in emerging nations are anticipated to lure market players in expanding their businesses in these economies, strengthening the market’s condition over the next few years.


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports